A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
Phase 2 study of subjects with ALK positive, advanced NSCLC who have failed up to 3 prior therapies. The study will take place globally at multiple study centers. Subjects will be enrolled to receive ganetespib one time per week for three weeks followed by a rest week; and will repeat this schedule until the cancer gets worse or the subject is unable to tolerate ganetespib. The primary goal of the study is to determine how ganetespib is tolerated and how active it is in ALK positive NSCLC.
Checked against the public recordLast updated May 20, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Synta Pharmaceuticals Corp.
- Interventions being studied
- Drug: Ganetespib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Males or females aged 18 years or older * Pathological confirmation of advanced NSCLC * Evidence of a translocation or an inversion event involving the ALK gene locus * ECOG Performance Status 0 or 1 Exclusion Criteria: * Prior therapy with ALK-targeted agents * Prior treatment with Hsp90 inhibitor * Known EGFR activating mutation * Presence of active or untreated central nervous system (CNS) metastases
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Synta Pharmaceuticals Investigative SiteTampa, Florida
- Synta Pharmaceuticals Investigative SiteCleveland, Ohio
- Synta Pharmaceuticals Investigative SiteHamilton, Ontario
- Synta Pharmaceuticals Investigative SiteOttawa, Ontario
- Synta Pharmaceuticals Investigative SiteToronto, Ontario
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 20, 2015. Always confirm current availability with the study team.